Skip to main content

Dynavax Technologies(DVAX-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low15.49
Day High15.50
Open:15.49
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Dynavax Technologies

Select a category then submit the form to load news
Motley Fool
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
Motley Fool
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
Motley Fool
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
Motley Fool
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish
Tipranks
Dynavax Completes Merger and Prepares Nasdaq Delisting
Motley Fool
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
Tipranks
Dynavax Agrees to Be Acquired by Sanofi in Merger
Tipranks
Dynavax (DVAX) was downgraded to a Hold Rating at William Blair
Motley Fool
Why Dynavax Stock Soared Today
Tipranks
Evercore ISI Reaffirms Their Buy Rating on Dynavax (DVAX)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dynavax (DVAX) and QuidelOrtho (QDEL)
Tipranks
Dynavax Technologies Advances in Pneumonic Plague Vaccine Study
Tipranks
Dynavax Announces Management Restructuring Changes
Tipranks
Citizens JMP Sticks to Their Buy Rating for Dynavax (DVAX)
Tipranks
Goldman Sachs Keeps Their Sell Rating on Dynavax (DVAX)
Tipranks
Dynavax (DVAX) Gets a Buy from TD Cowen
Tipranks
Dynavax Announces Positive Results for Shingles Vaccine
Motley Fool
Dynavax (DVAX) Q2 Revenue Jumps 29%
Tipranks
William Blair Keeps Their Buy Rating on Dynavax (DVAX)
Motley Fool
Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript
Motley Fool
Dynavax Technologies (DVAX) Q3 2024 Earnings Call Transcript
Motley Fool
Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript
Barchart
3 'Strong Buy' Small-Caps With 27% to 146% Upside Potential
People and teaching - shutterstock_1808942746
Motley Fool
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
Motley Fool
Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript
Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
Motley Fool
Dynavax Technologies (DVAX) Q3 2023 Earnings Call Transcript
PR Newswire
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
PR Newswire
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Motley Fool
Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript
PR Newswire
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
PR Newswire
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023

Profile

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.